3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Select Water Holdings LLC, a subsidiary of Select Water Solutions, priced $900 million of 7.625% senior notes maturing November 1, 2034, upsized from $800 million and sold at par, with closing expected October 21, 2026. Net proceeds of approximately $882.6 million, plus cash on hand, will fund part of the cash consideration for the pending Pilot Water Solutions acquisition and repay the term loan and revolving credit facility obligations. The notes add $900 million of debt, and if the Pilot Water Acquisition is not completed by March 1, 2027, most of the notes must be redeemed.
$900 million of 7.625% senior notes due November 1, 2034, upsized from $800 million and priced at par
Approximately $882.6 million in net proceeds after the initial purchasers' discount and estimated offering expenses; closing expected October 21, 2026
Proceeds fund part of the Pilot Water Acquisition cash consideration and repay the term loan in full
If the Pilot Water Acquisition is not completed by March 1, 2027, the issuer must redeem notes equal to the principal less $450 million
Northrim BanCorp reported third-quarter 2026 net income of $14.4 million, or $0.63 per diluted share, down from $27.1 million, or $1.20 per share, a year earlier. The results include an $8.8 million impairment on a single $20.0 million loan relationship at Northrim Funding Services, which the company expects to reduce after-tax earnings by $6.7 million, or $0.29 per diluted share, and it says resolution will take several quarters.
Q3 2026 net income $14.4 million ($0.63 per diluted share), versus $15.3 million ($0.68) in Q2 2026 and $27.1 million ($1.20) in Q3 2025
Impairment charge of $8.8 million tied to one $20.0 million relationship; after-tax effect of about $6.7 million or $0.29 per diluted share
Net interest income rose 5% from the prior quarter to $38.9 million and 10% from a year earlier
Proposed PBCO Financial acquisition, all-stock, expected to close in the first quarter of 2027
Opus Genetics presented interim clinical data from its OPGx-BEST1 and OPGx-LCA5 gene therapy trials at Retina in Rio 2026 on October 14, 2026, and furnished the press release and slides in this 8-K. The company said the data are interim and based on small participant groups, and it expects Phase 3 dosing for OPGx-LCA5 to begin in the fourth quarter of 2026.
OPGx-BEST1 low-dose Cohort 1: three of four evaluable participants (75%) showed improved retinal sensitivity in the treated transitional zone.
OPGx-LCA5 adults showed sustained improvements in visual acuity and light sensitivity through 24 months; three pediatric participants showed results through six months.
OPGx-BEST1 high-dose Cohort 2 has completed enrollment with 11 participants.
Phase 3 dosing for OPGx-LCA5 is expected in the fourth quarter of 2026.
Mount Logan Capital's indirect subsidiary MLC US Holdings signed Amendment No. 6 to its credit agreement, which waives certain specified defaults linked to the September 29, 2026 merger of Alternative Credit Income Fund into BC Partners Lending Corporation and the cancellation of a $15.0 million promissory note. The filing also discloses a revenue share agreement that gives the subsidiary a share of adviser fees, but it does not report any financial results or a dollar amount for that share.
Amendment No. 6 dated October 9, 2026 includes a limited waiver of specified events of default under the Credit Agreement.
The SCIM Promissory Note, originally $15.0 million, was cancelled on September 29, 2026 in exchange for rights to a 29.88% revenue share of BCPA's management and incentive fees, less certain sales force compensation.
Net amount owed to Sierra Crest Investment Management under the terminated Services Agreement was initially calculated at approximately $3.4 million, to be repaid quarterly by offset against revenue share payments.
No early termination penalties were incurred in connection with the note cancellation or the Services Agreement termination.
Varonis Systems agreed to be acquired by Proofpoint, a Thoma Bravo portfolio company, in an all-cash transaction valued at about $6.3 billion. Varonis shareholders would receive $49.75 per share, a 52% premium to the June 22, 2026 closing price of $32.71, and the deal requires shareholder and regulatory approval, with closing expected in the first half of 2027. Varonis shares would stop trading on Nasdaq and the company would become private.
Merger consideration of $49.75 per share in cash, a 52% premium to the $32.71 close on June 22, 2026 and 17% above the $42.35 close on September 1, 2026
Transaction valued at about $6.3 billion, or about 53x LTM free cash flow and 8.4x LTM revenue
Varonis must pay Proofpoint a $211.7 million termination fee in specified circumstances; Proofpoint would pay a $423.3 million reverse termination fee in specified circumstances
Expected to close in the first half of 2027; either party may terminate if the merger is not completed by July 15, 2027, subject to a three-month regulatory extension
Biohaven entered into a Collaboration and License Agreement with Ono Pharmaceutical dated October 8, 2026, granting Ono an exclusive, royalty-bearing license to develop and commercialize its MoDE pan IgG degrader portfolio in Japan, South Korea, Taiwan and the ASEAN countries. Biohaven retains rights outside that territory, including the United States, Europe and China. The deal provides Biohaven up to $100 million in near-term payments, which the company says is non-dilutive capital.
Ono pays a one-time, non-refundable upfront payment of $80 million upon closing.
Biohaven is eligible for another $20 million upon a milestone, tied to Ono's stability test results and its election to continue development; the press release anticipates this milestone within a year.
Ono will pay royalties of approximately 20% on net sales of licensed products in the licensed territory, subject to specified reductions.
Ono may terminate the agreement for convenience on specified prior written notice, in whole or by product or country.
Cenntro Inc. entered into a sales agreement dated October 9, 2026, with Pacific Century Securities, LLC, allowing it to sell up to $100 million of common stock through the agent over time. The company is not obligated to sell any shares, and the agent has no obligation to buy shares on its own account, so the actual amount raised is not set. Shareholders could face dilution if the company sells shares under the program.
Sales agreement dated October 9, 2026, covers up to $100,000,000 of common stock at the market.
Pacific Century Securities, LLC receives a 3.5% commission on gross proceeds from each sale.
Shares are offered under a prospectus supplement dated October 9, 2026, filed October 13, 2026, on Form S-3 effective February 12, 2026.
The company paid $50,000 at signing under an engagement letter dated September 1, 2026, with up to $50,000 more due at the first placement closing.
SPACSphere Acquisition Corp. and Mobilewalla signed an amendment to their Business Combination Agreement that would expand the combined company's board from five to seven directors, effective at closing of the merger. The amendment sets out who would hold the seats, including two Mobilewalla designees, one SPACSphere designee and four independent directors, and the rest of the original agreement remains in effect.
Combined company board would grow from five to seven directors, effective at the merger closing
Mobilewalla designees: Anindya Datta (Class III) and Boris M. Gutin; SPACSphere designee: Bala Padmakumar
Four independent directors, including George Brody, John Garner and Stephen Markscheid; the fourth will be appointed before the Form S-4 is declared effective
ChronoScale Holdings reported fiscal first quarter 2027 revenue of $41.5 million, up 148% from a year earlier, driven by a new customer's AI infrastructure hardware resale arrangements. Net loss from continuing operations widened to $26.4 million, or $0.18 per share, from $11.2 million, or $0.08 per share, and Adjusted EBITDA fell to $5.9 million from $9.4 million, so shareholders face higher losses even as sales grew.
Revenue was $41.5 million versus $16.7 million in the prior-year quarter, up 148%.
Net loss from continuing operations was $26.4 million, or $0.18 per share, compared with $11.2 million, or $0.08 per share.
Total net loss was $42.5 million, including a $16.1 million loss from discontinued operations tied to the Legacy Ekso Business, which was sold on September 30, 2026.
As of August 31, 2026, cash and cash equivalents were $15.2 million; the company reported $328.2 million in aggregate customer prepayments received after quarter end.
Actinium Pharmaceuticals said Matt David, M.D., began serving as chief financial officer on October 14, 2026, succeeding no one named in the filing. He previously was chief financial officer of CorMedix Inc. and will lead finance, accounting, capital markets and investor relations.
Dr. David commenced service as CFO and principal financial officer on October 14, 2026, under an offer letter dated September 30, 2026.
Offer terms include a $450,000 annual base salary, a 40% target annual bonus, and a $150,000 sign-on bonus.
He received an option on 250,000 shares and 325,000 restricted stock units under the 2026 Employment Inducement Award Plan, adopted by the Board on September 2, 2026 without stockholder approval.
Enerpac Tool Group approved a long-term incentive program on October 13, 2026, granting performance-vesting stock awards to four named executive officers linked to its previously announced acquisition of Specialized Fabrication Equipment Group LLC (SFE Group). The awards vest based on fiscal 2028 net sales and adjusted EBITDA, and are forfeited if the acquisition does not close by November 30, 2026.
Named executive awards at target level total $510,000: Darren M. Kozik $200,000, Benjamin J. Topercer $125,000, Noah N. Popp $110,000, Eric T. Chack $75,000.
Half of each award depends on net sales goals and half on adjusted EBITDA goals for fiscal 2028; payout ranges from 0% at threshold to 200% at maximum.
All awards under the program are forfeited for no consideration if the SFE Group acquisition does not close on or before November 30, 2026.
Tianci International subsidiaries agreed on October 12, 2026 to have Linknex Limited, a Hong Kong company, build an enterprise AI integration platform for their businesses. Payment will combine $146,700 in cash with 180,000 newly issued Tianci common shares, to be issued within twenty business days after the shares are listed on Nasdaq, so the deal adds a share issuance that could dilute existing holders.
Agreement dated October 12, 2026 between subsidiaries RQS United Group Limited and Roshing International Co., Limited and Linknex Limited
Consideration: $146,700 in cash plus 180,000 shares of Tianci common stock
Shares to be issued within twenty business days after listing on Nasdaq
A Statement of Work with scope, milestones and acceptance criteria is yet to be signed
Capital Southwest preliminarily estimated its results for the quarter ended September 30, 2026, which is its second quarter of fiscal 2027. The company said the estimates may change materially after its quarter-end closing procedures, so shareholders should wait for its full results on November 2, 2026.
Preliminary pre-tax net investment income estimate: $0.58 to $0.59 per share
Preliminary net investment income estimate: $0.56 to $0.57 per share
Preliminary net asset value per share as of September 30, 2026: $16.62 to $16.67
Finalized Q2 fiscal 2027 results due November 2, 2026 after market close; webcast on November 3, 2026 at 11:00 a.m. Eastern Time
Shoe Station Group entered into an amendment to its credit agreement with Wells Fargo as administrative agent, extending the $100 million revolving credit facility's maturity to October 15, 2031 and revising its pricing. The amendment also raises the annual restricted-payment basket to $40 million and permits up to $35 million of secured headquarters-related debt, giving the company more room for payments and borrowing.
Revolving credit facility of $100 million now matures October 15, 2031.
Base Rate loans carry a margin of 0.00% to 1.00%; Adjusted Term SOFR loans carry 1.00% to 2.00%, based on Consolidated Total Leverage Ratio.
Annual restricted-payment basket increased to $40 million; up to $35 million of secured debt for corporate headquarters permitted.
Amendment permits certain sale-leaseback transactions involving the Evansville, Indiana property and any corporate headquarters property.
Loop Industries reported its second quarter fiscal 2027 results for the three months ended August 31, 2026, with revenue of $117 thousand from engineering services to the India joint venture, compared with zero a year earlier. The net loss narrowed to $2.99 million from $3.20 million, and the company had total available liquidity of $1.9 million at August 31, 2026. The company also rescaled its planned India facility to 45 KTA to reduce capital needs, but its Special Committee is still seeking financing for its equity contribution.
Q2 revenue was $117 thousand, all from engineering services provided to the India JV, versus $0 in the prior-year quarter.
Net loss was $2.99 million, or $0.06 per share, versus $3.20 million, or $0.07 per share, a year earlier.
Cash operating expenses were $1.6 million, a decrease of $0.8 million year over year.
Total available liquidity was $1.9 million at August 31, 2026; the company says there can be no assurance its funding sources will be sufficient to reach commercial start-up.
Hyster-Yale's Board appointed Matthew Cornell, formerly a Stanley Black & Decker executive, as Senior Vice President and Chief Financial Officer effective November 1, 2026. CEO Rajiv K. Prasad will remain the principal financial officer until the Form 10-Q for the quarter ending September 30, 2026 is filed, after which Cornell takes over that role on November 4.
Matthew Cornell appointed SVP and CFO effective November 1, 2026
Initial base salary set at $605,000 per year, plus incentive and equity awards
Prasad serves as principal financial officer until the Q3 2026 Form 10-Q; Cornell assumes the role November 4
Cornell previously served as President and General Manager at Stanley Black & Decker from October 2022 to October 2025
Orion Group Holdings disclosed that Executive Vice President and Chief Financial Officer Alison G. Vasquez entered into a new employment agreement effective October 12, 2026, replacing her 2025 offer letter. The agreement sets a $480,000 base salary, a 75% target bonus and expanded severance terms, including enhanced payments after a change in control.
Base salary set at $480,000 per year, subject to review; target annual bonus 75% of base salary
Initial term ends December 31, 2026, renewing automatically for one-year periods
Severance without cause or for good reason: one year of salary continuation; after a change in control within 12 months, three years of salary continuation plus a lump sum of three times the most recent annual bonus
Agreement effective October 12, 2026; filed October 15, 2026, with the full text as Exhibit 10.1
Pinterest entered into an amended and restated five-year, $700 million revolving credit facility on October 15, 2026, replacing its previous $500.0 million facility from October 2022. The filing states there were no amounts outstanding under the new facility as of October 15, 2026, and that the company is in compliance with all covenants, so the agreement adds borrowing capacity without current debt.
Five-year, $700 million revolving credit facility with JPMorgan Chase Bank, N.A. as administrative agent, replacing a $500.0 million facility
Borrowings accrue at SOFR plus a 1.25% margin, or an alternative base rate plus 0.25%, at the company's election
Covenants include a maximum net leverage ratio of 3.50 to 1.00, and secured liens on substantially all domestic assets that are released upon an investment grade period
No amounts outstanding under the facility as of October 15, 2026
As of October 13, 2026, United States Natural Gas Fund, LP amended its ISDA 2002 Master Agreement with Société Générale, lowering the Total Net Assets Decline Event termination trigger from $1.5 billion to $200 million. The company says the reduced threshold reflects its performance and is intended to ensure the trigger is not hit absent a credit event.
Amendment dated as of October 13, 2026 to the ISDA 2002 Master Agreement originally entered into June 13, 2022
TNA Decline Event Additional Termination Event threshold reduced from $1.5 billion to $200 million
Full agreement filed as Exhibit 10.16 and incorporated by reference
Mesabi Trust's trustees said no distribution has been declared this quarter and none will be paid in November 2026, compared with $0.34 per Unit declared for the same period last year. The trustees cited a July 30, 2026 royalty payment of $1,807,779 from Cleveland-Cliffs, which included no bonus royalty and was below the $5,300,287 received in July 2025, leaving unitholders with no quarterly payout.
No distribution declared this quarter and none to be paid in November 2026, versus $0.34 per Unit a year earlier
July 30, 2026 royalty payments from Cleveland-Cliffs totaled $1,807,779, with no bonus royalty, compared with $5,300,287 in July 2025
Cliffs reported zero bonus royalties in each 2026 quarterly report, with Silver Bay shipments priced below the $71.70 per ton threshold
Third-quarter royalty payments are due October 30, 2026, with a summary to be filed on Form 8-K afterward
Datavault AI appointed Jeffrey Tirman to its board, effective October 12, 2026, filling the seat vacated by Wendy Wilson's resignation. NYIAX designated Tirman under the Merger Agreement for its acquisition by the company, and the filing says Wilson resigned to allow that appointment, not due to any disagreement. Tirman's appointment ties board composition to the NYIAX deal, and he holds 26 million DVLT shares through his family office.
Wendy Wilson resigned from the board on October 11, 2026, effective October 12, 2026; the filing says this was not due to any disagreement.
Jeffrey Tirman was appointed to the board on October 11, 2026, effective after Wilson's resignation, and was designated by NYIAX under the Merger Agreement.
Tirman holds 26 million DVLT shares through Abri Capital Ltd., according to the press release.
As a non-employee director, Tirman receives $60,000 per year in cash compensation and a 125,000-share restricted stock award under the 2018 Plan, subject to an S-8 registration statement.
On October 14, 2026, Crescent Energy Finance LLC signed a sixteenth amendment to its credit agreement that permits the previously announced acquisition of Eagle Ford assets from a Devon Energy subsidiary and allows up to $2.0 billion of unsecured bridge debt to help fund part of the cash price. The company also said it expects cash paid on commodity derivatives of $144 million for the third quarter and $383 million for the first nine months of 2026, both preliminary. The filing does not state the acquisition price, so shareholders can't yet gauge the deal's scale relative to the new debt.
Sixteenth Amendment dated October 14, 2026 permits the Devon EF Assets Acquisition from Devon Energy Production Company, L.P.
Permits an up to $2.0 billion 364-day unsecured bridge credit facility to fund part of the cash consideration.
Permits additional pari passu secured term loan debt, capped at the lesser of a borrowing base formula and 50.0% of total elected commitments plus permitted pari passu debt.
Expected cash paid on commodity derivatives: $144 million for Q3 2026 and $383 million for nine months ended September 30, 2026.
Simmons First National Corporation reported third quarter 2026 net income of $47.1 million, or $0.32 diluted EPS, down from $66.7 million and $0.46 in the second quarter of 2026, while total revenue rose to $251.2 million from $248.6 million. Adjusted diluted EPS rose to $0.54 from $0.50, excluding $43.2 million in pre-tax items such as branch rightsizing, severance and certain professional services costs. For shareholders, GAAP earnings declined while adjusted earnings and net interest margin improved, and management plans to outline future financial targets at an Investor Day in December.
Net income $47.1 million in 3Q26 vs $66.7 million in 2Q26; diluted EPS $0.32 vs $0.46
Adjusted diluted EPS $0.54 vs $0.50 in 2Q26; certain items totaled $43.2 million pre-tax
Net interest margin rose 8 basis points to 3.92%; total deposits fell to $18.6 billion from $19.7 billion
Nonperforming loans rose to $179.9 million from $166.1 million; about $161 million remains under the 2026 buyback program, with no repurchases in the quarter
Four Greenlane Holdings subsidiaries executed assignments for the benefit of creditors on September 30, 2026, with Philip J. von Kahle as assignee, who will liquidate their assets and distribute proceeds to creditors under Florida law. The Court in Miami-Dade County assumed jurisdiction over the assets on October 9, 2026, and the filing notes the related deconsolidation of these subsidiaries and possible claims against the Company, so shareholders face the risk of losing value tied to these businesses.
Four subsidiaries assigned to Philip J. von Kahle on September 30, 2026: Warehouse Goods LLC, Greenlane Holdings, LLC, KIM International, LLC and Kush Supply Co. LLC
Petitions filed October 9, 2026 in Circuit Court of the Eleventh Judicial Circuit, Miami-Dade County, Complex Business Division
Proceedings not yet consolidated and no judge assigned as of the filing date; assignments do not release the subsidiaries from their liabilities
First Tracks Biotherapeutics agreed on October 15, 2026 to sell 6,106,870 common shares at $32.75 each to institutional investors, for expected gross proceeds of about $200 million before placement fees and expenses. The deal is expected to close on October 19, 2026, and proceeds will fund general corporate purposes, including clinical development of ANB033. The new shares are unregistered and will be issued to investors who must be covered by a resale registration statement filed within 30 days after closing, so existing shareholders face dilution from the issuance and possible future resales.
Sale of 6,106,870 common shares at $32.75 per share, for about $200 million in gross proceeds before fees and expenses
Expected closing on October 19, 2026, subject to customary conditions
Placement agents are Leerink Partners, Piper Sandler, UBS Investment Bank and Wells Fargo Securities
Company had 35,909,814 common shares outstanding as of October 12, 2026; resale registration due within 30 days after closing
On October 14, 2026, FreightCar America entered a Stockholder Agreement with three OC III entities that collectively own about 48.8% of its common stock, including warrants. The company also amended and terminated its August 5, 2026 Rights Agreement, so the rights expired at the close of business that day and common holders no longer hold rights under the plan.
OC III entities collectively own about 48.8% of common stock, including warrants, per a July 2, 2026 Schedule 13D/A
Rights Agreement dated August 5, 2026 was amended to accelerate expiration from July 5, 2027 to close of business October 14, 2026
Board must review transfers of shares to any holder above 20%; agreement ends at the earlier of the fourth anniversary or when the group falls to 20% or less
Company agreed not to adopt future rights plans with an ownership trigger below 20%
Crescent Biopharma said in an October 15, 2026 press release that it has enrolled patients in chemotherapy combination cohorts of its ASCEND trial for CR-001, and that the FDA has cleared its CR-002 ADC for a Phase 1/2 trial. The filing gives timing for several clinical data readouts but reports no revenue, earnings, or financial results, so it is a pipeline update rather than a financial report for shareholders.
Initial CR-001 monotherapy data from ASCEND expected in the first quarter of 2027, covering more than 125 patients
Chemotherapy combination cohort data anticipated in mid-2027; Phase 3 trials of CR-001 planned to start in early 2028
CR-002 received FDA IND clearance in October 2026; APOLLO Phase 1/2 trial planned to start in the fourth quarter of 2026, with initial data in the second half of 2027
Cohen & Steers reported third-quarter 2026 revenue of $157.4 million, up about 3% from the second quarter and about 11% from a year earlier, driven by higher average AUM. GAAP diluted EPS was $0.81, down from $0.95 in the second quarter and flat year over year, while adjusted diluted EPS rose to $0.89 from $0.85. AUM ended the quarter at $95.9 billion, down 4.2% from $100.1 billion, as market depreciation of $5.1 billion outweighed net inflows of $1.6 billion.
Revenue: $157.4 million, up about 3% from $152.7 million in Q2 2026 and about 11% from $141.7 million in Q3 2025
GAAP diluted EPS $0.81 vs. $0.95 in Q2 2026 and $0.81 in Q3 2025; adjusted diluted EPS $0.89 vs. $0.85 in Q2 2026
AUM $95.9 billion at September 30, 2026, down from $100.1 billion at June 30, 2026, with net inflows of $1.6 billion
Board declared a $0.67 quarterly dividend per share, paid August 20, 2026
Frazier Life Sciences Acquisition Corp. II, a special purpose acquisition company, closed its initial public offering of 7,500,000 Class A ordinary shares at $10.00 per share on October 15, 2026, raising $75 million in gross proceeds. The company also sold 300,000 private placement shares to its sponsor for $3 million, and $75 million of the proceeds was placed in a trust account for public shareholders, who can only access it through a business combination or redemption, with a 24-month deadline from the IPO closing.
IPO of 7,500,000 Class A ordinary shares at $10.00 per share closed October 15, 2026, for gross proceeds of $75 million; shares trade on Nasdaq Capital Market under FLSC
Sponsor Frazier Life Sciences Holdings II, LLC bought 300,000 private placement shares at $10.00 each, for $3 million
$75 million placed in trust account held by Continental Stock Transfer & Trust Company; company has 24 months from IPO closing to complete an initial business combination
Frazier Life Sciences Public Fund, L.P. committed to buy at least 2,500,000 Class A shares at $10.00 each, a minimum of $25 million, at the closing of a business combination
Avnet and Avnet Holding Europe BV signed Amendment No. 3 to the company's credit agreement on October 13, 2026, with Bank of America, N.A. as administrative agent. The amendment increases total commitments by $1.0 billion to $2.75 billion and raises the maximum additional commitments the company can request to $1.0 billion. For shareholders, it expands the company's available borrowing capacity under the facility, and the filing states that other terms remain substantially the same.
Total commitments under the credit agreement increase by $1.0 billion to $2.75 billion.
Maximum additional commitments the company can request rise to $1.0 billion.
The SOFR credit spread adjustment to the interest rate is eliminated.
The amendment is dated October 13, 2026 and is filed as Exhibit 10.1; the original agreement is dated January 17, 2025.
J.B. Hunt Transport Services reported third quarter 2026 results for the period ended September 30, 2026, with total operating revenue up 20% to $3.68 billion and diluted earnings per share of $1.82 versus $1.76 a year earlier. Operating income rose 2% to $247.1 million, but operating income as a percentage of gross revenue declined, and the company cited higher purchased transportation, fuel costs and insurance claims.
Q3 2026 total operating revenue was $3.68 billion, up 20%; revenue excluding fuel surcharge rose 13%.
Net earnings were $172.4 million versus $170.8 million a year earlier; diluted EPS was $1.82 versus $1.76.
Operating income was $247.1 million, up 2%; Dedicated Contract Services operating income fell 22% to $81.7 million.
In the third quarter the company bought back about 704,000 shares for about $174 million and had about $619 million left under its repurchase authorization.
Prudential disclosed preliminary, unaudited third-quarter 2026 figures ahead of its November 3, 2026 earnings release, showing an estimated $140 million reduction in Japan Businesses pre-tax adjusted operating income from the Prudential of Japan sales suspension. The company also estimated alternative investment income of its General Account $15 million to $35 million above near-term expectations, and it reclassified its International Businesses segment as Japan Businesses effective the third quarter of 2026. The figures are not final and financial closing procedures are not complete.
Prudential of Japan sales suspension estimated to reduce Japan Businesses pre-tax adjusted operating income by about $140 million in the quarter ended September 30, 2026, including one-time costs
General Account alternative investment income estimated at $15 million to $35 million above near-term expectations for the quarter
PGIM assets under management were $1.47 trillion as of September 30, 2026; PGIM other related revenues were about $20 million on an adjusted operating income basis
Brazil and Mexico operations moved to Divested and Run-off Businesses; AFP Habitat moved to Retirement; revised second quarter 2026 supplement furnished as Exhibit 99.1
Blue Owl Finance LLC, an indirect subsidiary of Blue Owl Capital Inc., signed a fourth amendment to its credit agreement on October 14, 2026. The revolving credit commitment rises to $3,225,000,000 (potentially $3,870,000,000 if conditions are met), the maturity is extended to October 14, 2031, and pricing is reduced, which lowers borrowing costs for the subsidiary.
Revolving commitment increased to $3.225 billion, with a potential increase to $3.87 billion if conditions are satisfied
Maturity extended from the existing date to October 14, 2031
Term SOFR loan margin reduced to 77.5 to 127.5 basis points; commitment fee rate reduced to 7.0 to 16.5 basis points
MUFG Bank, Ltd. serves as administrative agent; the Company itself is not a party to the amended agreement
On October 15, 2026, subsidiary NCL Corporation closed a $950.0 million offering of 8.750% senior notes due 2031, with net proceeds of approximately $941.7 million. The company used the proceeds, with cash on hand, to redeem its 6.125% notes due 2028 and to repay and prepay other borrowings, and it amended its revolving credit facility to raise lender commitments to $2,801.0 million. For shareholders, the filing shows a debt refinancing and a larger revolver, but the new notes carry a higher interest rate than the notes they replaced.
$950.0 million of 8.750% senior notes due October 15, 2031 closed October 15, 2026; net proceeds approximately $941.7 million before estimated fees and expenses.
Proceeds, with cash on hand, used to redeem all outstanding 6.125% notes due 2028 and to repay approximately $376.3 million of revolver borrowings and prepay approximately $42.2 million of export-credit facilities.
Revolving loan commitments increased from $2,486.0 million to $2,801.0 million; maturity is January 22, 2030, subject to conditions tied to 2027 exchangeable notes.
Pride of America Ship Holding and Norwegian Epic were added as guarantors; Norwegian Dawn and Norwegian Spirit were released as guarantors.
The Charles Schwab Corporation reported third-quarter 2026 results for the quarter ended September 30, 2026, in an 8-K furnishing its earnings press release as Exhibit 99.1. Net revenues rose 17% year-over-year to a record $7.2 billion, and GAAP diluted earnings per share rose 29% to $1.62 from $1.26. The results show growth in both revenue and profit, while GAAP results include $151 million of pre-tax transaction-related costs that the company excluded from its adjusted figures.
Net income was $2.9 billion for the quarter, up 23% from $2.4 billion a year earlier; adjusted diluted EPS was $1.69.
Core net new assets were $190.4 billion, up 38% versus the third quarter of 2025.
Pre-tax transaction-related costs totaled $151 million; the company also hosted a Fall Business Update for institutional investors on October 15, 2026.
Vroom's subsidiary UACC completed an asset-backed securities deal on October 15, 2026, selling about $292.1 million of subprime auto contracts to a trust that issued $234.2 million of notes. Separately, on October 13, 2026, Vroom amended its convertible note agreement to raise commitments from $50.0 million to $60.0 million, with the added funds provided by insiders Mudrick and Annox.
UACC sold about $292,059,710 of subprime motor vehicle retail installment sales contracts to a special purpose subsidiary, which the trust then acquired.
The trust issued $234,232,000 of asset-backed notes in five classes, with fixed rates from 5.09% (Class A) to 9.59% (Class E); notes are obligations solely of the trust, not UACC or Vroom.
Convertible note commitments rose from $50.0 million to $60.0 million under the amendment dated October 13, 2026.
Mudrick, the controlling stockholder, and Annox, which is controlled by Independent Executive Chair Robert J. Mylod, Jr., provided the increased commitments.
Cyngn Inc. received a Nasdaq letter on October 14, 2026, saying its stock closed below $1.00 for 30 consecutive business days, so it no longer meets Nasdaq's minimum bid price requirement. The notice has no immediate effect on the listing, and the company has 180 calendar days, until April 12, 2027, to regain compliance. Shareholders face the risk of delisting if the company cannot regain compliance, and the company states there is no assurance it will do so.
Nasdaq notice dated October 14, 2026 cites closing bid price below $1.00 for 30 consecutive business days
Compliance deadline is April 12, 2027; compliance requires a closing bid of at least $1.00 for 10 consecutive business days
If not compliant by April 12, 2027, the company may be eligible for an additional 180 days, potentially requiring a reverse stock split
Company states there can be no assurance it will regain or maintain compliance
Fortune Brands signed a definitive agreement to sell its Fiberon composite decking business to a subsidiary of Inteplast Group Corporation for $160 million in cash. The company expects an additional non-cash impairment charge estimated at about $175 million to $205 million, on top of the $221.2 million impairment recorded as of June 27, 2026. Closing is subject to regulatory approval and is expected within 60 days.
Definitive purchase agreement executed October 15, 2026, with a subsidiary of Inteplast Group Corporation for $160 million in cash.
Expected additional non-cash impairment charge of approximately $175 million to $205 million relating to Fiberon.
Earlier impairment of $221.2 million recorded as of June 27, 2026, within the Outdoors segment.
Closing subject to regulatory approval and expected within 60 days.
NB Bancorp, Inc., the holding company for Needham Bank, reported third quarter 2026 net income of $23.1 million, or $0.58 per diluted share, up from $21.1 million, or $0.53 per diluted share, in the prior quarter. Operating net income, a non-GAAP measure, was $23.8 million, or $0.60 per diluted share, while net charge-offs rose to 0.31% of average loans from 0.07%, mainly due to a $4.0 million charge-off. The Board also declared a $0.07 per share dividend.
Net income $23.1 million, or $0.58 per diluted share, versus $21.1 million, or $0.53, in the prior quarter
Net interest margin declined to 3.97% from 4.00%; total loans rose 5.3% in the quarter to $6.77 billion
Net charge-offs were $5.2 million, or 0.31% of average loans, including a $4.0 million charge-off on a previously reserved loan
Dividend of $0.07 per share is payable November 12, 2026, to shareholders of record as of October 29, 2026
IB Acquisition Corp. set December 16, 2026 as the date of its first annual stockholder meeting since its IPO, to be held virtually, and fixed October 28, 2026 as the record date for voting. The company says the meeting should help it regain compliance with a Nasdaq rule it was cited for in October 2026 after not holding an annual meeting within twelve months of its fiscal year end.
Annual Meeting set for Wednesday, December 16, 2026, at 10:00 a.m. Eastern Time, virtually via live webcast
Record date is close of business on October 28, 2026
Stockholder proposals for the proxy statement must be received by close of business on October 26, 2026
Nasdaq notified the company on October 5, 2026 that it was not in compliance with Listing Rule 5620(a)
Sow Good Inc. and its subsidiary Sow Good Tanzania Inc. signed an Extension Letter with four sellers, including Ryzon Materials Limited, amending the Sunset Date of a previously announced Share Purchase Agreement to October 30, 2026. The filing does not describe the purchase price or the deal's business terms, and it provides no reason for the extension, so shareholders have limited detail on the outcome.
Extension Letter signed October 15, 2026, amending the Share Purchase Agreement dated April 20, 2026
The Sunset Date under the agreement is now October 30, 2026
The SPA was previously amended by a Deed of Amendment dated August 21, 2026
SUNation Energy amended a secured revolving line of credit with MBB Energy, LLC, an entity controlled by two of the company's executives, extending the maturity date to April 15, 2027. The line's capacity had previously been raised to $1.5 million, and drawn loans carry 8% annualized interest, so the company's reliance on related-party borrowing continues.
Maturity date extended from October 15, 2026 to April 15, 2027, unless sooner repaid, amended or terminated
Aggregate capacity of the line of credit is $1.5 million, raised from $1 million in an April 14, 2026 amendment
Independent Bank Corp. reported third quarter 2026 net income of $89.7 million, or $1.90 per diluted share, up from $81.8 million, or $1.70 per share, in the second quarter. Higher net interest income drove the gain, while nonperforming loans rose to $125.7 million, mainly due to one office real estate loan.
Net income of $89.7 million versus $81.8 million in Q2 2026; diluted EPS of $1.90 versus $1.70
Net interest income rose $9.7 million to $220.7 million; net interest margin was 3.89%, up 4 basis points
Nonperforming loans increased to $125.7 million from $103.6 million, driven primarily by one office real estate loan
Repurchased about 679,000 shares for $57.4 million; about $93 million remains under the $200 million buyback plan
Alcoa reported third quarter 2026 results on October 15, 2026, with net income attributable to Alcoa of $483 million, or $1.81 per diluted share, up from $407 million in the second quarter. Revenue fell 7% sequentially to $3.7 billion, and adjusted EBITDA excluding special items declined to $789 million from $901 million, so shareholders see higher reported profit alongside weaker sequential operating measures. The company also reaffirmed its 2026 production and shipment projections and said it closes the AliGroup acquisition in the first half of 2027.
Revenue was $3.704 billion, down from $3.966 billion in Q2 2026 but up from $2.995 billion in Q3 2025.
Adjusted earnings were $1.82 per share, down from $2.12 in Q2 2026; adjusted net income was $485 million.
Cash balance ended the quarter at $4.4 billion, including $2.6 billion of financing obtained for the AliGroup acquisition.
For Q4 2026, Aluminum segment Adjusted EBITDA is expected to face about $30 million of unfavorable raw material and maintenance impacts, and interest expense is projected at about $185 million for the year.
Endovia Health Sciences amended its equity line of credit agreement with C/M Capital Master Fund, LP, raising the beneficial ownership limit on the investor from 4.99% to 9.99%, effective immediately. The change allows the investor to hold a larger stake under the facility, which could increase potential share issuance and dilution for existing shareholders, though the filing does not state any amount of shares or proceeds.
Beneficial ownership limit raised from 4.99% to 9.99% under the Purchase Agreement, effective October 15, 2026
Parties also waived notice requirements and other provisions inconsistent with the Letter Agreement
Original Securities Purchase Agreement dated September 19, 2025 was filed as Exhibit 10.3 to a September 25, 2025 8-K
Investor's resales are covered by Form S-1 (File No. 333-298112), declared effective August 24, 2026
Arrow Electronics said Eric Nowak, who has served the company for 22 years, will retire at the end of March 2027, and he will step down as President, Global Enterprise Computing Solutions, effective December 31, 2026. Rodney Clark, who previously held leadership roles at Cisco, Johnson Controls, Microsoft, and IBM, is expected to start on November 9, 2026, and will take over Nowak's duties. The filing says Nowak is retiring for personal reasons and not because of a disagreement with the company.
Eric Nowak informed the company on October 12, 2026, that he will retire at the end of March 2027 after 22 years with the company.
Nowak steps down as President, Global Enterprise Computing Solutions, effective December 31, 2026, and his duties will transfer to Rodney Clark.
Rodney Clark's employment is expected to begin November 9, 2026.
Nowak will remain an employee in an advisory role until retirement to assist with the transition; the filing says he is retiring for personal reasons.
OPKO Health and its subsidiary BioReference Health agreed on October 14, 2026, to sell certain assets of BioReference's clinical and anatomic pathology testing business to Laboratory Corporation of America Holdings. The buyer would pay $722 million in cash at closing, plus up to $150 million more over up to ten years based on sales of the 4Kscore prostate cancer test. Closing depends on customary conditions, including HSR antitrust clearance, and is not subject to a financing condition.
Cash purchase price of $722 million at closing, subject to adjustments based on Business revenues at closing
Up to $150 million in additional cash over up to ten years, based on revenue from sales of the 4Kscore test by the buyer
Closing requires HSR antitrust clearance; either party may terminate if the deal has not closed by April 14, 2027, which may be extended by mutual agreement
Buyer would pay OPKO a termination fee of $28,880,000 if the deal ends due to failure to obtain HSR clearance or other required approvals
NextTrip reported fiscal second-quarter revenue of $546,687, down about 28% from $757,648 a year earlier, and said it deliberately prioritized platform and product work over near-term revenue. Six-month revenue rose about 122% to $1,998,422, and deferred revenue was about $1.2 million at August 31, 2026. Operating expenses, net loss and loss per share were not included and will appear in the Form 10-Q.
Q2 revenue (three months ended August 31, 2026): $546,687, versus $757,648 in the prior-year quarter, a decline of about 28%
Six-month revenue: $1,998,422, versus $896,475 in the prior-year period, an increase of about 122%
Deferred revenue of about $1.2 million at August 31, 2026, supported in part by cruise bookings, generally recognized when travel is fulfilled
Net loss, loss per share and operating expenses were not disclosed and will be included in the Form 10-Q
Mustang Bio said Nasdaq granted it an additional 180-calendar day period, until April 12, 2027, to regain compliance with the $1.00 minimum bid price rule after it missed the October 12, 2026 deadline. The company must close at or above $1.00 for at least 10 consecutive business days in that period, and it has said it may effect a reverse stock split if necessary. If it does not regain compliance, Nasdaq will issue a delisting notice, and the company says there is no assurance it will meet all continued listing requirements.
Nasdaq granted an additional 180-calendar day grace period, through April 12, 2027, letter dated October 13, 2026
Compliance requires a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days, generally no more than 20
Company has stated it may effect a reverse stock split if necessary; failure to comply would lead to a delisting notice
Innovative Eyewear, Inc. (LUCY) received a Nasdaq notice on October 9, 2026, saying its common stock closed below $1.00 for 30 consecutive business days, so it is not meeting the minimum bid price rule. The notice has no immediate effect on the stock's listing, but the company has until April 7, 2027 to regain compliance, and failure could lead to delisting proceedings.
Nasdaq notice dated October 9, 2026; stock closed below $1.00 for 30 consecutive business days
Company has 180 calendar days, until April 7, 2027, to regain compliance
Regaining compliance requires a closing bid of at least $1.00 for 10 consecutive business days
Company may seek a second 180-day period or request a Nasdaq Hearings Panel review; no assurance either will be granted
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.